Estrella Immunopharma (ESLA) Common Equity (2021 - 2026)

Estrella Immunopharma (ESLA) has reported Common Equity for 6 consecutive years, with -$7.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 21.93% year-over-year to -$7.4 million in Q2 2026; TTM through Jun 2026 was -$7.4 million, a 21.93% decrease from a year earlier, with the FY2025 full-year figure at -$10.4 million, down 7312.12% from the prior year.
• Common Equity was -$7.4 million for Q2 2026 at Estrella Immunopharma, down from -$5.3 million in the prior quarter.
• Over five years, Common Equity peaked at $10.1 million in Q3 2023 and troughed at -$11.7 million in Q2 2023.
• A 5-year average of -$2.3 million and a median of -$2.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 363.43% in 2023 and sank 7312.12% in 2025, its largest moves.
• Over 5 years, Common Equity stood at -$6.5 million in 2022, then surged by 239.73% to $9.0 million in 2023, then slumped by 98.41% to $143731.0 in 2024, then slumped by 7312.12% to -$10.4 million in 2025, then advanced by 28.31% to -$7.4 million in 2026.
• The last three Common Equity figures came in at -$7.4 million (Q2 2026), -$5.3 million (Q1 2026), and -$10.4 million (Q4 2025), per Business Quant data.